Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis

Eurosurveillance

Volumn 19, Issue 6, 2014, Pages

  Castilla, J ^a,b   Martinez Baz I ^a,b   Navascues A ^c   Fernandez Alonso, M ^d   Reina, G ^d   Guevara, M ^a,b   Chamorro, J ^c   Ortega, M T ^e   Albeniz E ^f   Pozo, F ^g   Ezpeleta, C ^c  

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f Navarre Health Service   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; INFLUENZA VACCINE; TRIPLE VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; EPIDEMIC; FEMALE; HEALTH CARE; HOSPITAL; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; MUTATION; NURSING HOME; OUTPATIENT; VACCINATION; VIRUS CHARACTERIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LABORATORIES; LOGISTIC MODELS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SEASONS; SENTINEL SURVEILLANCE; SPAIN; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84896702726     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.6.20700     Document Type: Article

References (21)

1. Adlhoch C, Broberg E, Beauté J, Snacken R, Bancroft E, Zucs P, et al. Influenza season 2013/14 has started in Europe with influenza A(H1)pdm09 virus being the most prevalent subtype. Euro Surveill. 2014; 19(4): pii=20686.
2. Sistema de Vigilancia de la Gripe en Espa-a. Informe semanal de Vigilancia de la Gripe en Espa-a. Semana 04/2014 (20 - 26 de enero 2014). [Weekly report of the influenza surveillance system in Spain 4/2014]. No 378. Madrid: Instituto de Salud Carlos III; 30 January 2014. Spanish. Available from: http://vgripe.isciii.es/gripe/documentos/20132014/boletines/grn042014.pdf
3. European Centre for Disease Prevention and Control (ECDC). Weekly influenza surveillance overview. 7 February 2014. Stockholm: ECDC: 2014. Available from: http://www.ecdc.europa.eu/en/publications/Publications/influenza-surveillance-overview-7-feb-2014.pdf
4. Recommended composition of the influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. Wkly Epidemiol Rec. 2013; 88(10):101-14.
5. Valenciano M, Ciancio B; I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill. 2012; 17(39):pii=20281.
6. Castilla J, Morán J, Martínez-Artola V, Reina G, Martínez-Baz I, García Cenoz M, et al. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill. 2011; 16(7): pii=19799.
7. Instituto de Salud Pública y Laboral de Navarra. Protocolo de vacunación antigripal 2013-2014. [Influenza vaccination protocol 2013-2014]. Boletín Informativo. 2013; 74:1-4. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/265602/BOL74INTCampana20132014.pdf
8. Aguilar I, Reyes M, Martínez-Baz I, Guevara M, Albéniz E, Belza MJ, et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill. 2012; 17(17):pii=20154.
9. European Commission. Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Union. Luxembourg: Publications Office of the European Union. 18.6.2008: L 159. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:159:0046:0090:EN:PDF
10. Castilla J, Cía F, Zubicoa J, Reina G, Martínez-Artola V, Ezpeleta C. Influenza outbreaks in nursing homes with high vaccination coverage in Navarre, Spain, 2011/12. Euro Surveill. 2012; 17(14):pii=20141.
11. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013; 18(5):pii=20388.
12. Martínez-Baz I, Martínez-Artola V, Reina G, Guevara M, Cenoz MG, Morán J, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health. 2013;13:191. http://dx.doi.org/10.1186/1471-2458-13-191
13. Castilla J, Martínez-Baz I, Martínez-Artola V, Fernández-Alonso M, Reina G, Guevara M, et al. Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis. Euro Surveill. 2013; 18(7):pii=20404.
14. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en Espa-a. Temporada 2012-2013 (Desde la semana 40/2012 hasta la semana 20/2013). Sistema de Vigilancia de la Gripe en Espa-a. [Report of the Influenza surveillance in Spain, season 2012-2013]. Madrid: Instituto de Salud Carlos III; 2013. Spanish. Available from: http://vgripe.isciii.es/gripe/documentos/20122013/InformesAnuales/Informe_Vigilancia_GRIPE_2012-13_18sep2013.pdf
15. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization. Summary Europe, December 2013. Stockholm: ECDC; 2014. Available from: http://www.ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-dec-2013.pdf
16. Bragstad K, Emborg HD, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13 - a rapid epidemiological and virological assessment. Euro Surveill. 2013; 18(6):pii=20397.
17. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada's sentinel surveillance network, January 2014. Euro Surveill. 2014; 19(5):pii=20690.
18. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010; 28(46):7381-7388. http://dx.doi.org/10.1016/j.vaccine.2010.09.010
19. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010; 363(21):2036-2044. http://dx.doi.org/10.1056/NEJMra1002842
20. Godoy P, Castilla J, Delgado-Rodríguez M, Martín V, Soldevila N, Alonso J, et al. Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization. Prev Med. 2012; 54(6):434-439. http://dx.doi.org/10.1016/j.ypmed.2012.04.009
21. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(1):1-24.